Fine-Tuned Clinical LLMs vs General AI Models: What the Evidence Actually Shows

The intuition is reasonable enough. A language model trained on millions of PubMed abstracts, clinical notes, and ICH guidance documents should outperform one trained on a general internet corpus when you ask it to assess protocol eligibility criteria or draft a statistical analysis plan. Specialization, in most professional domains, produces expertise. Why would AI be different?

As it turns out, the relationship between domain-specific training and clinical task performance is considerably more complicated than that intuition suggests. Evidence accumulated through 2024 and into 2025 has begun to challenge several assumptions the clinical AI community has relied on. For sponsors, CROs, and the medical writing teams who must eventually deploy these tools in regulated environments, the distinction between fine-tuned clinical LLMs and large general-purpose models is not merely academic. It determines where AI can reduce manual effort under qualified review, where the evidence is still too thin to act on, and how to structure the human oversight layer that regulated workflows increasingly require.

Why the Stakes Are High in Clinical Trial Contexts

Protocol quality failures are not a marginal problem. A 2025 policy analysis published in npj Digital Medicine found, drawing on Cochrane reviews, that over 40% of clinical trials involve flawed protocols, contributing to enrollment failures, regulatory delays, and wasted resources ^[1]. That figure provides a compelling backdrop for AI-assisted protocol development, but it also sets the bar for what any model, specialized or general, needs to clear before it operates in a regulated clinical context.

The document types AI models must handle in clinical research are genuinely difficult. Clinical trial protocols, informed consent forms (ICFs), statistical analysis plans, investigator brochures, and development safety update reports carry regulatory weight. A protocol eligibility criterion that is ambiguous or internally inconsistent does not just create operational friction; it can compromise data integrity, trigger major amendments, and in rare cases create patient safety risks. The same standard applies to AI-generated content: factual errors and hallucinated citations are not inconveniences that reviewers can quickly filter out. They propagate.

Against that backdrop, the question of which model architecture to deploy is inseparable from a more fundamental question: which approach produces outputs that a qualified reviewer can trust, verify, and defend to a regulatory authority?

The Current Landscape of Clinical AI Models

Two broad categories of language model are being evaluated and deployed in clinical trial contexts.

The first are general-purpose large language models (LLMs), including commercially available systems such as GPT-4o, Gemini 2.5 Pro, and Claude. These are trained on broad web-scale corpora, exhibit strong reasoning and text generation capabilities, and have shown substantial performance on medical benchmarks without any domain-specific fine-tuning. A 2025 study published in NEJM AI evaluated ten leading LLMs on clinical reasoning benchmarks, including GPT-4o, OpenAI's o3 and o4-mini, Anthropic's Claude 3.5 Sonnet, Google's Gemini 2.5, and several others, examining their performance under zero-shot, few-shot, and reasoning-prompted conditions ^[2].

The second category encompasses domain-specific or fine-tuned clinical models. These include BioGPT, developed by Microsoft Research and pre-trained from scratch on 15 million PubMed abstracts ^[3]; Med-PaLM 2, Google's medically fine-tuned model that reached 86.5% accuracy on the MedQA benchmark ^[4]; and a growing cohort of open-source variants including OpenBioLLM, Meditron, PMC-LLaMA, and MedAlpaca. The premise behind these models is that exposure to domain-specific text during pretraining or fine-tuning sharpens performance on tasks where general models are weakest: reading and producing regulatory language, interpreting clinical trial terminology, and applying ICH guidelines correctly.

There is also a third approach generating considerable interest, one that complicates the two-way comparison: retrieval-augmented generation (RAG), in which a general-purpose model is paired with a curated external knowledge base at inference time. RAG does not require retraining the model; it can ground generation in retrieved, verifiable documents when retrieval quality, citation mapping, and prompt constraints are working correctly. Whether RAG-enhanced general models outperform standalone fine-tuned ones, or whether RAG should be layered on top of fine-tuned models, is one of the more actively debated questions in clinical AI.

What the Benchmarks Reveal

Fine-Tuned Clinical Models Do Not Consistently Win

One of the more surprising findings from recent systematic evaluation is that fine-tuned biomedical LLMs often perform worse than their general-purpose counterparts on tasks they were ostensibly built for, particularly when evaluated on data outside their fine-tuning corpora.

A study available on arXiv evaluated biomedical LLMs on clinical case challenges from the New England Journal of Medicine and JAMA, as well as tasks from the Clinical Language Understanding Evaluation (CLUE) benchmark. The researchers found that biomedical models generally performed worse than their general-purpose counterparts, especially on tasks beyond pure medical knowledge retrieval. Smaller biomedical models showed the most pronounced underperformance: OpenBioLLM-8B achieved 30% accuracy on NEJM cases, while Llama-3-8B-Instruct, the general-purpose model of equivalent scale, scored 64.3% ^[5]. Larger models showed smaller gaps, but the general trend held. Fine-tuning on biomedical data did not reliably improve performance across diverse evaluation tasks.

The researchers concluded that fine-tuning may cause a narrowing effect, where models lose some of the general reasoning capacity acquired during pretraining in exchange for domain-specific knowledge that does not transfer well to unseen tasks ^[5]. They identified RAG as a potentially more effective route to enhancing biomedical capability without those performance trade-offs.

The picture is more nuanced at specific task levels. A comprehensive benchmark of LLMs in clinical decision-making (preprint) found that open-source medical LLMs did consistently outperform their general-purpose counterparts on structured reasoning datasets with discrete answer choices, with fine-tuned models such as MedAlpaca-7B, PMC-LLaMA-13B, and ClinicalCamel-70B outperforming their base LLaMA-2 counterparts at corresponding parameter scales ^[6]. However, on open-ended clinical language generation tasks, such as treatment recommendation with free-text outputs, all models performed poorly regardless of whether they were fine-tuned or general-purpose, with F1 scores below 20% across the board ^[6].

The implication is that fine-tuned clinical models tend to produce narrower improvements, mostly on structured tasks with discrete answer choices, while both categories remain limited on the kinds of open-ended document generation that clinical research operations actually require.

Trial Matching: Where the Data Favor Large General Models

Patient-to-trial matching is one of the most actively studied clinical AI tasks, and the comparison between fine-tuned and general models here is particularly instructive. A 2025 systematic review (preprint) examined 31 studies drawn from 126 unique articles on LLM-based approaches to clinical trial matching published between 2020 and 2025. In studies that directly compared model architectures, GPT-4 consistently outperformed other models, including fine-tuned alternatives, on matching accuracy and eligibility extraction, though at higher per-query cost ^[7].

The cost consideration is real, and sponsors and CROs operating at scale may process tens of thousands of patient records during a recruitment period. The same systematic review noted that fine-tuning smaller open-source models on domain-specific matching datasets is a viable strategy when data privacy constraints make cloud-hosted proprietary APIs infeasible ^[7]. When patient data cannot leave a hospital's network, a locally deployed fine-tuned model may be the most practical option available, even if its raw accuracy is somewhat lower.

An earlier study explored this trade-off by fine-tuning open-source LLaMA variants on a synthetic dataset generated by GPT-4. The fine-tuned open-source models achieved performance parity with GPT-3.5 and approached GPT-4-level accuracy on patient-trial matching, addressing cost and reproducibility disadvantages of proprietary systems ^[8]. Using large general models to generate training data for smaller fine-tuned ones is increasingly adopted as a middle path.

Protocol Writing and Document Generation: The RAG Advantage

For document generation tasks, specifically protocol sections, ICFs, and other regulatory documents, the clearest performance signal in recent literature comes not from fine-tuned models alone, but from combining general models with RAG architectures.

A 2025 study published in the journal Clinical Trials generated protocol sections across multiple disease areas and trial phases, evaluating outputs across four quality dimensions: clinical thinking and logic, transparency and references, medical and clinical terminology, and content relevance. Off-the-shelf general LLMs scored above 80% on terminology and content relevance but fell to 40% or below on clinical thinking and logic, and on transparency and references, the two dimensions that most directly affect regulatory acceptability ^[9]. When the same models were augmented with RAG, drawing on regulatory guidance documents and ClinicalTrials.gov data, clinical thinking and reference scores increased to approximately 80%, bringing them in line with the stronger dimensions ^[9].

For ICF drafting, a research system called InformGen, which combines optimized document parsing with RAG and a human-in-the-loop review layer, achieved near 100% compliance with 18 core FDA regulatory rules across a benchmark dataset of 900 clinical trial ICFs, outperforming an unaugmented GPT-4o model by up to 30% on compliance metrics (preprint). With human reviewer intervention, InformGen achieved over 90% factual accuracy, compared with 57% to 82% for the unaugmented model ^[10].

What these results suggest is that architecture matters more than the choice between fine-tuned and general. Grounding a model in verified, current source documents at inference time produces more consistent regulatory-quality outputs than either retraining the model on historical clinical text or relying on a general model's parametric knowledge alone.

Hallucination: The Shared Liability

Across both model categories, hallucination remains the most serious obstacle to deployment in regulated clinical contexts. A framework for assessing hallucination and clinical safety in LLM-generated medical summaries, published in npj Digital Medicine in 2025, examined 12,999 clinician-annotated sentences drawn from 18 experimental configurations. The researchers observed an aggregate hallucination rate of 1.47% at the sentence level, with an omission rate of 3.45% ^[11]. Taken at face value, those numbers seem manageable. The more consequential finding was that a substantial proportion of identified hallucinations carried clinical significance, meaning they were not minor phrasing errors but content-level inaccuracies with potential implications for patient safety or data integrity ^[11].

A 2025 preprint study evaluated LLMs on 1,500 questions drawn from 100 pivotal clinical trials and found baseline hallucination rates of 31% in LLaMA-3.3-70B before mitigation strategies were applied ^[12]. The same study, conducted in a research setting, demonstrated that a continuous hallucination detection-and-refinement framework called CHECK reduced those rates to 0.3% under controlled experimental conditions, and raised GPT-4o's USMLE passing rate by 5 percentage points to 92.1% ^[12]. These are research-setting results, and CHECK has not been validated for production clinical decision-support systems. The finding nonetheless illustrates a direction: hallucination in clinical LLMs is not intractable, but it requires deliberate mitigation architecture rather than accepting model-generated text as inherently trustworthy.

Neither a fine-tuned clinical model nor a general one is ready to produce submission-quality regulatory documents without a verification layer, whether that is RAG grounding, a hallucination-detection classifier, or structured human review with source-by-source confirmation.

Regulatory and Validation Considerations

The regulatory environment for AI in clinical development has matured considerably. In January 2025, the FDA published draft guidance titled "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products" ^[13]. The guidance is draft and non-binding, but it describes a risk-based credibility assessment framework that sponsors may use when AI outputs are intended to support regulatory decision-making on safety, efficacy, or quality. The framework draws on the agency's experience reviewing more than 500 submissions that included AI components since 2016 and applies regardless of whether the underlying model is fine-tuned or general-purpose ^[13].

Separately, the FDA published final guidance in December 2024 on Predetermined Change Control Plans (PCCPs) for AI-enabled device software functions, with the current PDF issued August 18, 2025, governing how AI models used in diagnostic or monitoring devices can be updated without triggering full re-review ^[14]. Fine-tuned clinical models that are periodically retrained on new clinical data may constitute software modifications requiring documentation under the PCCP framework, depending on the intended use and risk classification of the device.

ICH E6(R3), finalized at Step 4 on January 6, 2025, represents the first complete overhaul of the Good Clinical Practice guideline since the 2016 E6(R2) addendum ^[15]. The Step 2 public consultation version had been issued in May 2023; the final guideline was adopted by ICH regulatory members in January 2025, with the EU implementing Principles and Annex 1 from July 23, 2025, and the FDA issuing its corresponding final guidance on September 8, 2025 ^[15]. The guideline's emphasis on data governance, fit-for-purpose systems, reliable trial records, and risk-proportionate oversight creates a practical expectation that AI-assisted processes in regulated trials can demonstrate their outputs are accurate, auditable, and consistent with source documents. That expectation is not unique to AI, but it bears directly on how AI-generated content should be reviewed and documented.

RAG-based systems offer a structural advantage in this context over parametric-only models: when a model cites a document retrieved at inference time, a reviewer can verify the citation directly. That traceability is meaningful only if the retrieval pipeline, citation mapping, source access, and reviewer workflow are themselves validated for the specific use case. Neither RAG nor fine-tuning eliminates the need for expert review; they shape what expert review has to verify.

Task-by-Task Architecture Guidance

Different clinical research tasks call for different model architectures. The table below summarizes the current state of evidence, and the sections that follow provide the detail behind each row.

Evidence strength varies considerably across these task categories, and results from preprint studies should be treated as directional until independently replicated in peer-reviewed settings. The sections below provide the detail behind each row.

Structured information extraction (eligibility criteria parsing, adverse event coding, lab value normalization) is where fine-tuned models such as BioClinicalBERT have demonstrated clear, reproducible advantages. These are bounded tasks with discrete outputs, where fine-tuning on annotated corpora produces measurable precision gains. In clinical named entity recognition benchmarks, BioClinicalBERT achieved F1 scores of 0.901 on standard datasets; GPT-4 with careful prompt engineering approached but did not match that precision in zero-shot conditions ^[16].

Patient eligibility screening benefits from RAG-augmented general models when patient data can be sent to an external API, and from fine-tuned open-source models when data privacy requirements make local deployment preferable. The RECTIFIER system, a RAG-enabled GPT-4 framework evaluated across 1,894 patient records in a heart failure trial, achieved sensitivity of 92.3% and specificity of 93.9%, compared with sensitivity of 90.1% and specificity of 83.6% for trained study staff screening the same criteria ^[17]. For institutions where external API calls are not viable, fine-tuned open-source models with performance approaching GPT-3.5 levels represent an established practical alternative ^[8].

Regulatory document drafting (protocols, ICFs, investigator brochures, DSURs) currently favors RAG-grounded general models over both standalone fine-tuned models and ungrounded general approaches, based on the evidence available to date. The off-the-shelf general model performs acceptably on terminology and content relevance but falls short on clinical logic and sourcing. Adding RAG anchored to current regulatory guidance and trial-specific documents brings those weaker dimensions in line with the stronger ones. Published evidence on full regulatory document quality from fine-tuned models alone remains limited.

Clinical reasoning and decision support remains the most contested domain. Large general models with strong reasoning capabilities have outperformed fine-tuned medical LLMs on complex case-based tasks in recent benchmarks ^[2], while fine-tuned models retain advantages on structured multiple-choice tasks ^[6]. No current evidence supports unsupervised deployment in either category for tasks that directly affect protocol design or patient safety decisions.

How Kitsa Approaches This Problem

Document generation in clinical research is not a generic text problem. An ICF drafted from a protocol must track every eligibility criterion, every intervention description, and every safety reporting threshold without introducing inconsistencies. A DSUR must reflect the safety database accurately while conforming to ICH E2F format expectations. These are tasks where the source document is the ground truth, and any AI system generating regulated content must be anchored to it.

KScribe, Kitsa's AI-powered regulatory document generation platform, operates on this principle. Rather than relying on a model's parametric memory of what protocols or consent forms typically contain, it grounds generation in the specific documents a sponsor or CRO provides: the protocol, the investigator brochure, the trial master file. The output is traceable to its source, which is the baseline expectation for AI-assisted content that enters a regulated workflow. For teams evaluating clinical AI tools, the question worth asking of any vendor is not "is this a fine-tuned model or a general one?" but rather "can I verify where each claim in this output came from, and does that verification pathway stand up to qualified review?"

Key Takeaways

• •Fine-tuned biomedical LLMs do not consistently outperform large general models across clinical tasks; recent benchmarks show that smaller fine-tuned models can significantly underperform their general-purpose counterparts on unseen clinical data ^[5].
• •On patient-to-trial matching, GPT-4 and GPT-4o have outperformed fine-tuned alternatives in direct comparisons, though at higher per-query cost; fine-tuned open-source models are a practical path when patient data cannot leave an institution's network ^[7],[8].
• •For regulatory document generation, RAG-augmented general models have demonstrated stronger performance than either standalone fine-tuned or ungrounded general approaches, with clinical logic and sourcing quality roughly doubling when RAG is applied ^[9].
• •Hallucination remains a liability across both model categories and requires deliberate mitigation, whether RAG grounding, classifier-based detection, or structured human review with source verification ^[11],[12].
• •The FDA's January 2025 draft guidance describes a risk-based credibility assessment framework that sponsors may apply when AI outputs support regulatory decision-making; it is draft and non-binding ^[13].
• •ICH E6(R3), finalized January 2025, emphasizes data governance, fit-for-purpose systems, and reliable records, creating a practical expectation that AI-assisted regulated workflows can demonstrate output accuracy and auditability ^[15].
• •Architecture and grounding matter more than the fine-tuned versus general distinction when selecting AI tools for clinical document generation.

FAQ

References

Related Articles